Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | APAF1 | O14727 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.55 |
| ▸ | FDPS | P14324 | 17/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL2533633 | 0.98 | MEN1 (0.55) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 | |
| SCHEMBL4266804 | 0.96 | MEN1 (0.62) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 | |
| SCHEMBL5288264 | 0.96 | MEN1 (0.62) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 | |
| SCHEMBL5301127 | 0.96 | MEN1 (0.62) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 | |
| SCHEMBL5286011 | 0.96 | MEN1 (0.62) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 | |
| SCHEMBL5291994 | 0.96 | MEN1 (0.62) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 | |
| SCHEMBL5290107 | 0.96 | MEN1 (0.62) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 | |
| SCHEMBL5284351 | 0.96 | MEN1 (0.62) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 | |
| SCHEMBL5288678 | 0.96 | MEN1 (0.62) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 | |
| SCHEMBL5289982 | 0.96 | MEN1 (0.62) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8632914-B2 | Triazolium and imidazolium salts and uses thereof | UNIVERSITY HEALTH NETWORK (CA) | 2014-01-21 | — | — | US | disclosed |
| US-20110257235-A1 | TRIAZOLIUM AND IMIDAZOLIUM SALTS AND USES THEREOF | UNIVERSITY HEALTH NETWORK (CA) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257235-A1 | TRIAZOLIUM AND IMIDAZOLIUM SALTS AND USES THEREOF | ARG2, ARG1, CIT | MEN1 3327/4885HSP90AA1 1502/4885KMT2A 3456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.